ArticlePain2010
Peripheral endothelin B receptor agonist-induced antinociception involves endogenous opioids in mice.
Article in Pain, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Sovateltide (ILR-1620) Improves Motor Function and Reduces Hyperalgesia in a Rat Model of Spinal Cord Injury.Neurocritical care · 2024Article
- Oral Cancer Pain Includes Thermal Allodynia That May Be Attenuated by Chronic Alcohol Consumption.Pharmaceuticals (Basel, Switzerland) · 2023Article
- The Local Neuropeptide System of Keratinocytes.Biomedicines · 2021Review
- Endothelin-1 axes in the framework of predictive, preventive and personalised (3P) medicine.The EPMA journal · 2021Review
- A low pKa ligand inhibits cancer-associated pain in mice by activating peripheral mu-opioid receptors.Scientific reports · 2020Article
- Article
- Endothelin-1 Decreases Excitability of the Dorsal Root Ganglion Neurons via ETMolecular neurobiology · 2018Article
- Skin matters! The role of keratinocytes in nociception: a rational argument for the development of topical analgesics.Journal of pain research · 2017Review
- Direct Phenotypic Screening in Mice: Identification of Individual, Novel Antinociceptive Compounds from a Library of 734,821 Pyrrolidine Bis-piperazines.ACS combinatorial science · 2016Article
- The effects of beta-endorphin: state change modification.Fluids and barriers of the CNS · 2015Review
- Review of preclinical studies on treatment of mucositis and associated pain.Journal of dental research · 2014Review
- Recent advances in cancer pain management.F1000prime reports · 2014Review
- Evidence for the endothelin system as an emerging therapeutic target for the treatment of chronic pain.Journal of pain research · 2014Review
- Endothelin 1 in cancer: biological implications and therapeutic opportunities.Nature reviews. Cancer · 2013Review
- Endothelin B receptors exert antipruritic effects via peripheral κ-opioid receptors.Experimental and therapeutic medicine · 2012Article
- Analgesia targeting IB4-positive neurons in cancer-induced mechanical hypersensitivity.The journal of pain · 2012Article
- Biologic mechanisms of oral cancer pain and implications for clinical therapy.Journal of dental research · 2012Review
- Article
- New perspectives on the endothelin axis in pain.Pharmacological research · 2011Review
- Mechanical stimulation enhances endothelin-1 hyperalgesia.Neuroscience · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Endothelin-1 (ET-1) produced by various cancers is known to be responsible for inducing pain. While ET-1 binding to ETAR on peripheral nerves clearly mediates nociception, effects from binding to ETBR are less clear. The present study assessed the effects of ETBR activation and the role of endogenous opioid analgesia in carcinoma pain using an orthotopic cancer pain mouse model. mRNA expression analysis showed that ET-1 was nearly doubled while ETBR was significantly down-regulated in a human oral SCC cell line compared to normal oral keratinocytes (NOK). Squamous cell carcinoma (SCC) cell culture treated with an ETBR agonist (10(-4)M, 10(-5)M, and 10(-6) M BQ-3020) significantly increased the production of beta-endorphin without any effects on leu-enkephalin or dynorphin. Cancer inoculated in the hind paw of athymic mice with SCC induced significant pain, as indicated by reduction of paw withdrawal thresholds in response to mechanical stimulation, compared to sham-injected and NOK-injected groups. Intratumor administration of 3mg/kg BQ-3020 attenuated cancer pain by approximately 50% up to 3h post-injection compared to PBS-vehicle and contralateral injection, while intratumor ETBR antagonist BQ-788 treatment (100 and 300microg/kg and 3mg/kg) had no effects. Local naloxone methiodide (500microg/kg) or selective mu-opioid receptor antagonist (CTOP, 500microg/kg) injection reversed ETBR agonist-induced antinociception in cancer animals. We propose that these results demonstrate that peripheral ETBR agonism attenuates carcinoma pain by modulating beta-endorphins released from the SCC to act on peripheral opioid receptors found in the cancer microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.